5313492025-04-012025-06-305313492025-04-012025-06-30in-capmkt:OtherExpenses1Member5313492025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares531349PANACEABIONOTLISTEDINE922B01023PANACEA BIOTEC LIMITEDMain BoardEquity2025-04-012026-03-312025-08-142025-08-04INRLakhsQuarterlyFirst quarterSingle segmentVaccines2025-08-1411:30:002025-08-1416:45:00Not applicablefalsefalseThere is no default on loans.2025-04-012025-06-30UnauditedStandalone11225000004950000011720000006094000001140000060000025370000060000000477000002776000001260400000-884000000-884000000-21400000-214000000-670000000000-67000000200000-66800000613000001-1.09-1.0900-1.09-1.09Notes: <BR> 1. The financial results for the quarter ended June 30, 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 13, 2025 and August 14, 2025, respectively and have been reviewed by the statutory auditors of the Company. <BR> 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. <BR> 3. The consolidated financial results of the Company have been prepared by consolidating the Company's reviewed financial results for the respective periods with the reviewed financial results of the following wholly owned subsidiaries (“WOS”) and the Enterprises over which the Company exercises control (the Company, these subsidiaries and the enterprises hereinafter collectively referred to as “the Group”): <BR> (i) Indian WOS: Panacea Biotec Pharma Limited (“PBPL”) and Meyten Realtech Private Limited; <BR> (ii) Overseas WOS: Panacea Biotec (International) S.A. (“PBS”), Panacea Biotec Germany GmbH (WOS through PBS) and Panacea Biotec Inc. (WOS through PBPL); and <BR> (iii) Enterprises over which the Company exercises control*: PanEra Biotec Private Limited and Adveta Power Private Limited. <BR> *considered as a subsidiary for the purpose of consolidation as per Ind AS 110 <BR> <BR> 4. For the quarter ended June 30, 2025, the Company has incurred loss (before tax and exceptional items) of Rs.884 lakh (quarter ended June 30, 2024: loss of Rs.1,498 lakh) and the Group has incurred a loss (before tax and exceptional items) of Rs.476 lakh (quarter ended June 30, 2024: loss of Rs.1,979 lakh). The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis. <BR> Other2776000005. During the quarter ended June 30, 2025, the Group has recognised an exceptional income of Rs.1,132 Lakh under the “Exceptional Item” in the consolidated statement of profit and loss, which includes: <BR> (i) revenue of Rs. 858 lakh (quarter ended June 30, 2024: Nil), pursuant to the settlement agreement dated July 9, 2025 executed with Apotex Inc., USA (“Apotex”) to settle the ongoing dispute between Apotex and Company & PBPL; and <BR> (ii) revenue of Rs.274 lakh (quarter ended June 30, 2024: Rs.274 lakh), out of the remaining deferred consideration of Rs.2,111 lakh as at March 31, 2025, from sale of domestic pharmaceutical brands of PBPL. The balance deferred consideration of Rs.1,837 lakh (June 30, 2024: Rs.5,436 lakh) would be recognised in subsequent quarters / years and is shown as Contract Liability in the consolidated financial statement of Group. <BR> 6. The standalone financial results for the quarter and year ended March 31, 2025, includes deferred tax created for Rs 416 lakhs on account of adjustments pertaining to earlier years. The consolidated financial results for the quarter and year ended March 31, 2025, includes deferred tax charge for Rs 270 lakhs on account of adjustments pertaining to earlier years. <BR> 7. Amounts for the quarter ended March 31, 2025 represent the balancing amounts between the audited amounts for the full financial year and the published year to date amounts upto third quarter of the respective financial years, which had been subjected only to limited review. <BR> 8. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Ind AS 108, ‘Operating Segments’, the management has disclosed the segment information in the consolidated financial results. Accordingly, the segment information is given in the consolidated financial results of the Group for the quarter ended June 30, 2025. <BR> 9. The necessary certificate / report in respect of the above results in terms of requirement of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors. <BR> 10. Previous period amounts have been regrouped/ reclassified in compliance with Ind-AS to make them comparable with those of current period / year. <BR> 11. ‘0’ under “Rs. in Lakh” represents an amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. <BR> 12. The above results are also available on the Company’s website https://www.panaceabiotec.com <BR> Items that will not be reclassified to profit or loss20000020000000200000